|
1
|
Schröder FH, Hugosson J, Roobol MJ,
Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L,
Lilja H, et al ERSPC Investigators, : Screening and prostate cancer
mortality: Results of the European Randomised Study of Screening
for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet.
384:2027–2035. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wong MC, Goggins WB, Wang HH, Fung FD,
Leung C, Wong SY, Ng CF and Sung JJ: Global incidence and mortality
for prostate cancer: Analysis of temporal patterns and trends in 36
countries. Eur Urol. 70:862–874. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stewart BW and Wild CP: World Cancer
Report 2014. IARC Publications. (Lyon). 2014.
|
|
5
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Watson PA, Arora VK and Sawyers CL:
Emerging mechanisms of resistance to androgen receptor inhibitors
in prostate cancer. Nat Rev Cancer. 15:701–711. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ceder Y, Bjartell A, Culig Z, Rubin MA,
Tomlins S and Visakorpi T: The molecular evolution of
castration-resistant prostate cancer. Eur Urol Focus. 2:506–513.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nelson WG, De Marzo AM and Isaacs WB:
Prostate cancer. N Engl J Med. 349:366–381. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bandara KV, Michael MZ and Gleadle JM:
MicroRNA biogenesis in hypoxia. MicroRNA. 6:80–96. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu HC, Lai MT, Wu CI, Chen HY, Wan L, Tsai
FJ and Chen WC: E-cadherin gene 3-UTR C/T polymorphism is
associated with prostate cancer. Urol Int. 75:350–353. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Colden M, Dar AA, Saini S, Dahiya PV,
Shahryari V, Yamamura S, Tanaka Y, Stein G, Dahiya R and Majid S:
MicroRNA-466 inhibits tumor growth and bone metastasis in prostate
cancer by direct regulation of osteogenic transcription factor
RUNX2. Cell Death Dis. 8:e25722017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Meng X, Müller V, Milde-Langosch K,
Trillsch F, Pantel K and Schwarzenbach H: Diagnostic and prognostic
relevance of circulating exosomal miR-373, miR-200a, miR-200b and
miR-200c in patients with epithelial ovarian cancer. Oncotarget.
7:16923–16935. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Freitag MT, Radtke JP, Hadaschik BA,
Kopp-Schneider A, Eder M, Kopka K, Haberkorn U, Roethke M,
Schlemmer HP and Afshar-Oromieh A: Comparison of hybrid (68)Ga-PSMA
PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and
bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging.
43:70–83. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gundem G, Van Loo P, Kremeyer B,
Alexandrov LB, Tubio JM, Papaemmanuil E, Brewer DS, Kallio HML,
Högnäs G, Annala M, et al ICGC Prostate Group, : The evolutionary
history of lethal metastatic prostate cancer. Nature. 520:353–357.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Catalona WJ, Richie JP, Ahmann FR, Hudson
MA, Scardino PT, Flanigan RC, DeKernion JB, Ratliff TL, Kavoussi
LR, Dalkin BL, et al: Comparison of digital rectal examination and
serum prostate specific antigen in the early detection of prostate
cancer: Results of a multicenter clinical trial of 6,630 men. J
Urol. 197:S200–S207. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jemal A, Fedewa SA, Ma J, Siegel R, Lin
CC, Brawley O and Ward EM: Prostate cancer incidence and PSA
testing patterns in relation to USPSTF screening recommendations.
JAMA. 314:2054–2061. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Abd-Alazeez M, Ahmed HU, Arya M, Charman
SC, Anastasiadis E, Freeman A, Emberton M and Kirkham A: The
accuracy of multiparametric MRI in men with negative biopsy and
elevated PSA level - can it rule out clinically significant
prostate cancer? Urol Oncol. 32:45.e17–45.e22. 2014. View Article : Google Scholar
|
|
19
|
Lee SW, Hosokawa K, Kim S, Jeong OC, Lilja
H, Laurell T and Maeda M: A highly sensitive porous silicon
(P-Si)-based human kallikrein 2 (hK2) immunoassay platform toward
accurate diagnosis of prostate cancer. Sensors (Basel).
15:11972–11987. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Suzuki HI, Young RA and Sharp PA:
Super-enhancer-mediated RNA processing revealed by integrative
MicroRNA network analysis. Cell. 168:1000–1014.e15. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li XL, Andersen JB, Ezelle HJ, Wilson GM
and Hassel BA: Post-transcriptional regulation of RNase-L
expression is mediated by the 3-untranslated region of its mRNA. J
Biol Chem. 282:7950–7960. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Josson S, Gururajan M, Hu P, Shao C, Chu
GY, Zhau HE, Liu C, Lao K, Lu CL, Lu YT, et al: miR-409-3p/-5p
promotes tumorigenesis, epithelial-to-mesenchymal transition, and
bone metastasis of human prostate cancer. Clin Cancer Res.
20:4636–4646. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang X, Yuan T, Liang M, Du M, Xia S,
Dittmar R, Wang D, See W, Costello BA, Quevedo F, et al: Exosomal
miR-1290 and miR-375 as prognostic markers in castration-resistant
prostate cancer. Eur Urol. 67:33–41. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu XG, Zhu WY, Huang YY, Ma LN, Zhou SQ,
Wang YK, Zeng F, Zhou JH and Zhang YK: High expression of serum
miR-21 and tumor miR-200c associated with poor prognosis in
patients with lung cancer. Med Oncol. 29:618–626. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vrba L, Jensen TJ, Garbe JC, Heimark RL,
Cress AE, Dickinson S, Stampfer MR and Futscher BW: Role for DNA
methylation in the regulation of miR-200c and miR-141 expression in
normal and cancer cells. PLoS One. 5:e86972010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tao T, Liu D, Liu C, Xu B, Chen S, Yin Y,
Ang L, Huang Y, Zhang X and Chen M: Autoregulatory feedback loop of
EZH2/miR-200c/E2F3 as a driving force for prostate cancer
development. Biochim Biophys Acta. 1839:858–865. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ali S, Ahmad A, Banerjee S, Padhye S,
Dominiak K, Schaffert JM, Wang Z, Philip PA and Sarkar FH:
Gemcitabine sensitivity can be induced in pancreatic cancer cells
through modulation of miR-200 and miR-21 expression by curcumin or
its analogue CDF. Cancer Res. 70:3606–3617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Burk U, Schubert J, Wellner U, Schmalhofer
O, Vincan E, Spaderna S and Brabletz T: A reciprocal repression
between ZEB1 and members of the miR-200 family promotes EMT and
invasion in cancer cells. EMBO Rep. 9:582–589. 2008. View Article : Google Scholar : PubMed/NCBI
|
